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Circulating immune complexes in idiopathic glomerular disease. Circu-
lating immune complexes (CIC) could be found in the majority of 271
sera from 131 patients with idiopathic minimal change, membranous
and mesangial proliferative glomerulonephritis when a combination of
CIC assays detecting different properties of dC were used. In neither
individual patients nor in any of the three groups as a whole did CIC
levels reflect the state of the renal lesion. No correlation was found
between the class of immunoglobulin in the CIC and that deposited in
the kidney. With the exception of minimal change disease in which non-
Clq binding IgG CIC predominated, a range of dId was found in the
patients examined. The pattern of did detected did not allow different
forms of renal disease to be distinguished. IgA dId could be found in
mesangial proliferative glomerulonephritis both with and without IgA
deposition and in some patients with membranous and minimal change
disease, as well as in a high proportion of sera from 12 patients with the
Henoch-Schönlein syndrome. CIC size was estimated in six patients,
but only in one did a specific size of complex predominate. The CIC
which may be found in the majority of sera from patients with idiopathic
glomerulonephritis provide little information of clinical value; no direct
relationship can be demonstrated between the CIC found and the renal
lesion.
Immuns complexes circulants au cours des glomerulopathies idiopath-
iques. Des immuns complexes circulants (ICC) ont été trouvés dans Ia
majorit des 271 serums provenant de 131 malades atteints de gloméru-
lonéphrites idiopathiques avec lesions minimes, extra-membraneuse, et
proliferative endocapillaire en utilisant une sCrie de dosages des ICC
dCtectant leurs diverses propriétés. Chez aucun malade individuelle-
ment, ni dans aucun des 3 groupes dans leur ensemble, les concentra-
tions d'ICC ne reflétaient le degre de lesion rénale. II n'a pas Cté trouvé
de relation entre Ia classe d'immunoglobuline constituant les ICC et
celle déposCe dans le rein. Exception faite des lesions glomei-ulaires
minimes ofl des ICC a IgG ne liant pas le Clq predominaient, tout un
ensemble d'ICC a été trouvé chez les malades étudiés, et leur composi-
tion n'a pas permis de distinguer plusieurs types de néphropathies. Des
ICC a IgA ont eté trouvés au cours de glomérulonCphrites prolifératives
endocapillaires avec ou sans dCpôt d'IgA et de quelques glomérulonC-
phrites extramembraneuses ou a lesions glomerulaires minimes, aussi
bien que dans un grand nombre de serums de malades atteints de
purpura rhumatoIde. La taille des ICC a été estimée chez 6 malades,
mais chez un seul prCdominaient des ICC d'une taille specifique. Les
ICC retrouvés chez Ia plupart des malades atteints de glomérulopathie
idiopathique offrent donc peu d'informations d'intérêt clinique. Ii n'a
pas été dCmontré de rapport direct entre les ICC trouvCs et Ia lesion
rCnale.
A large proportion of adult human glomerulonephritis (GN) is
believed to be immune complex mediated [1]. Animal experi-
mental evidence indicates that the deposition of complexes
preformed in the circulation may lead to a range of histological
types of glomerulonephritis (GN) [2].
Assays designed to detect such circulating immune complex-
es (CIC) in human sera all have limitations of specificity and
sensitivity which prevent any one assay from detecting more
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than a proportion of the CIC present in pathological sera [31.
We have, therefore, used four assays detecting immunochemi-
cally distinct CIC in a survey of a large group of adults with
idiopathic GN. An attempt has been made to correlate the
levels, pattern, and size of CIC found with the renal biopsy
findings in minimal change, membranous and mesangial prolif-
erative GN. The results of an assay for IgA CIC in patients with
the Henoch-SchOnlein syndrome and other IgA nephropathies
were compared with those from patients with other mesangial
proliferative lesions and a small number of patients with mem-
branous and minimal change disease.
Methods
The patients were derived from those in a long-term study of
proteinuria being conducted in our department. All were seen at
intervals of four months or less. Patients with other conditions
known to cause GN were excluded. An assessment of renal
function was made by measurements of serum creatinine con-
centration, creatinine clearance, 24-hour urine protein excre-
tion, and counts of cells and casts in 2-hour urine collections.
No patient had a serum creatinine concentration greater than
200 moles/liter at the start of the study.
The diagnosis was based on a renal biopsy with, in the case of
minimal change disease, a response to steroid therapy. The
biopsies were examined by light and electron microscopy and
by indirect immunofluorescence for IgG, 1gM, IgA, and com-
plement components. Three groups of idiopathic patients were
studied: (1) Minimal change disease. Twenty-four patients with
minimal mesangial proliferation, no significant immunofluores-
cent deposits and only a fusion of foot processes on electron
microscopy; (2) Membranous GN. Thirty-six patients with
thickening and spiking of the glomerular basement membrane
on light microscopy, predominantly subepithelial dense depos-
its on electron microscopy and positive immunofluorescence
confined to the basement membrane; (3) Diffuse mesangial
proliferative GN. Sixty-two patients with diffuse mesangial
hypercellularity and positive immunofluorescence confined to
the mesangium with no antecedent history of an acute glomeru-
lonephritis. Three sub-groups were identified: (a) Predominant
1gM deposition : 30 patients; (b) Berger's IgA nephropathy: 13
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patients, recurrent macroscopic hematuria and prominent me-
sangial IgA deposition; (c) significant mesangial proliferative on
light microscopy but little or no mesangial IgA or 1gM deposi-
tion : 19 patients.
Henoch-SchOnlein Syndrome (HSS). Twelve patients with
the syndrome, all of whom had had extrarenal manifestations,
purpura, arthropathy, and/or alimentary involvement at some
stage, have been studied. Eleven had renal involvement, and
nine of these had a renal biopsy. All the biopsies showed
mesangial proliferation and mesangial IgA deposition.
Renal disease activity. Remission was defined as a resolution
of edema and/or hematuria, proteinuria < 300 mg/24 hours and
an absence of cells and casts from the urine. Relapse was
believed to have occurred when edema or hematuria recurred;
24-hour urine protein excretion exceeded 1 g and/or a urine
deposit became abnormal. Declining renal function was defined
as a continuing rise of the serum creatinine concentration in at
least three consecutive serum samples.
Blood samples were taken from all patients for CIC measure-
ments. Sequential samples were taken particularly from pa-
tients in relapse, those with evidence of continuing disease
activity and those with declining renal function.
Blood was kept at 37° C after venesection until separated,
within 2 hours, and the serum was then snap-frozen and stored
in multiple aliquots at —70° C. The sera were assayed as soon
after venesection as feasible, and in all cases within three
months. Aliquots of serum, having once been thawed for assay,
were discarded.
Assay techniques. IgG and IgA containing and Clq binding
complexes were measured by the latex agglutination inhibition
technique described by Levinsky and Soothill [41 with minor
modifications. The assays were performed on sera decomple-
mented by treatment with EDTA to release Clq; Clq was
absorbed on a Sepharose 4B gel coated with IgG. This step also
removed rheumatoid factors which would have interfered in the
assays and, because in the process sera were diluted 1:10, the
concentration of monomeric immunoglobulins was reduced to a
level at which they did not interfere in the assays. IgG CIC (IG)
were detected by their inhibition of the agglutination by rabbit
IgM-anti-IgG of 1.15 p. diameter, 0.8 p, latex coated with IgG
and IgA CIC (LA) by the inhibition of latex-IgA agglutination by
rabbit 1gM anti-IgA. Clq-binding CIC (Lc) were detected by
their inhibition of the agglutination of latex-IgG by purified
human Clq [5]. In each case the inhibition was estimated
quantitatively by counting the unaggregated latex particles in a
Coulter counter and expressing the result as the percentage
inhibition of the agglutination achieved in the absence of serum.
Chylomicra, which might interfere in this counting process
because of their size, were excluded by setting the thresholds
on the counter so that particles of < 0.6 p.3 (chylomicra —0.4 p.3)
were not counted.
The limits of normality of the assays were set using a panel of
60 normal sera. The concentration of the aggregant, rabbit 1gM
or human Clq, was adjusted thus altering the sensitivity of the
assay until 90% of the panel caused less than 20% inhibition of
agglutination; this level was taken as the upper limit of normal.
Reproducibility of the assays was monitored using known
concentrations of column-purified, heat aggregated immuno-
globulin, and multiple aliquots of known positive and negative
sera. The mean intra-assay variation of multiple assays of these
standards was less than 4%. The interassay variation increased
with an increasing degree of inhibition but did not exceed 10%.
The average deviation from the mean of a series of aggregated
IgG preparations in the L0 assay was 8%.
The LG, Lc, and LA assays were sensitive to less than 1
p.g/ml of aggregated immunoglobulin in decomplemented
serum.
The fourth assay used was a solid phase Clq technique (Sc)
[6]. Polystyrene tubes were coated with human Clq and EDTA-
treated serum added. After incubation and washing, the Clq-
binding IgG containing CIC were estimated quantitatively by
counting the binding of radiolabelled antihuman IgG. Of the
panel of 60 normal sera 90% caused the binding of < 0.4 p.g of
anti-IgG/ml of test serum. This binding was taken as the upper
limit of normal. The intra- and interassay variations of the Sc
assay were similar to the latex assays; it was sensitive to less
than 10 p.g of aggregated IgG in EDTA-treated serum.
Immune complex size was estimated by Sepharose 6B col-
umn chromatography. Serum decomplemented as for the latex
assays was run on a column calibrated with proteins of known
molecular weight. Each fraction collected between the void
volume ( > 4 x 106 daltons), and the albumin peak was
concentrated back to the starting volume by ultrafiltration and
assayed for LG complexes. Of six normal sera run on the
column, no fraction between the void volume and the elution
volume of monomeric IgG caused more than 5% inhibition and
inhibition below 5% in these fractions of pathological sera was
therefore ignored. The LG assay was sensitive to a wide range
of sizes of LgG aggregates but the L assay was relatively
insensitive to small (< 1 x 106 daltons) aggregates and thus
proved unsuitable for CIC sizing. The Sc assay was too
insensitive to detect CIC in column fractions.
Statistical methods. Correlations between results of the four
assays and between CIC levels and parameters of renal disease
were sought using Pearson's correlation coefficient and Ken-
dall's rank correlation.
Results
Two hundred and seventy-four sera from 134 patients, includ-
ing 37 sera from 12 HSS patients, were examined. Not all were
assayed by each CIC method. The LG assay was applied to
almost all sera and the Lc and Sc assays to as many of the sera
as was possible within three months of collection. The LA assay
was applied to the sera from patients with HSS and IgA
nephropathy and to a selection of sera from patients with other
mesangial proliferative, membranous and minimal change dis-
orders. The results of the four assays are detailed in Table 1.
In sequential sera from individual patients, levels of CIC
fluctuated from normal to abnormal; the number of individuals
whose sera were persistently positive or negative was small.
The actual levels of CIC in idiopathic GN were low. Most
positive sera caused less than 40% inhibition in the latex assays
(Fig. 1). Correlation coefficients were calculated between each
of the assays in each group of patients, but a significant
correlation was not found between any of the assays in any
group.
Minimal change disease. Thirty-three sera from 24 patients
were examined. Of these, 52% contained LG but only 25 and
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CIC assay
Any assayLG L S LA
Minimal change
Sera (33)
Patients (24)
Membranous
Sera (85)
Patients (36)
Mesangial proliferative
(1) 1gM
Sera (68)
Patients (30)
(2) Berger's IgA
Sera (19)
Patients (13)
(3) Others
Sera (32)
Patients (19)
Henoch-SchOnlein syndrome
Sera (37)
Patients (12)
45 (33)
54 (24)
44 (85)
70 (36)
52 (68)
74 (30)
61(18)
85 (13)
41(32)
37 (19)
45 (27)
78 (9)
19 (26)
25 (20)
40 (58)
53 (36)
57 (42)
80 (20)
27 (11)
38 (8)
38 (24)
37 (19)
36 (25)
50 (8)
12 (25)
16 (19)
18 (68)
26 (31)
13 (56)
19 (26)
20 (15)
25 (12)
20 (25)
22 (14)
31(23)
38 (8)
42 (12)
71 (7)
42 (36)
67 (15)
47 (30)
47 (17)
61(18)
62 (13)
14 (8)
17 (6)
64 (33)
83 (12)
64
62.5
67
94
75
87
95
100
56
53
73
92
The table represents the results of four CIC assays, LG, L, S, and LA in idiopathic ON, subdivided by histological appearances, and in the
Henoch-Schönlein syndrome. Both the proportion of patients having at least one positive result and the proportion of positive sera in each group is
shown. Results are expressed as the per cent positive; actual numbers of patients and sera involved are in parentheses.
16% contained Lc and Sc CIC, respectively. In at least one
assay (including LA), 63% of the sera were positive, and CIC
could be found at some time in 62.5% of patients.
Five patients were seen in relapse but in only one was a
relationship apparent between CIC levels and the duration of
relapse or proteinuria. In the group as a whole CIC levels did
not correlate with either the time from the onset, the most
recent relapse, or with the degree of proteinuria. Indeed, of 22
sera from 16 patients taken 12 months or more after the last
relapse when all were proteinuria-free and all treatment had
been withdrawn, 50% of the sera contained LG CIC.
Membranous GN. CIC could be found by at least one method
(including LA) in 67% of 85 sera from 36 patients. Sera from all
but four patients contained CIC at some time. The indolent
nature of the disorder limited the observations of the relation-
ship of CIC levels to changes in the state of disease in individual
patients. Two patients were followed into remission and in two
proteinuria was halved during the followup. A fifth patient was
followed into a relapse. In none of these five patients was a
relationship apparent between the results of any CIC assay and
the state of the disease.
In the group as a whole, the results of the CIC assays did not
correlate with a degree of proteinuria or with the length of time
elapsed from the onset or the relapse of the renal lesion. CIC
levels were no higher in 23 sera from 6 patients with declining
renal function than in patients with stable renal function.
Mesangial proliferative GN. Of the 119 sera examined 73%
contained CIC in at least one assay, and of the 62 patients in this
group 49 had CIC at some stage. A similar high incidence of a
variety of CIC was found in the I{SS patients, 9 of whom had
mesangial proliferative lesions.
No relationship emerged between dC assay results and renal
disease activity assessed as the duration of disease, degree of
proteinuria, or the decline in renal function in this group of
patients. Seven patients were seen in relapse and remission but
in none was a relationship found between activity of disease anddc.
LA CIC. This type of CIC could be found in most patients
with HSS. Levels could be related to the activity of disease in
two patients in relapse but not in two others, in one of whom
levels never exceeded 20%, the upper limit of normality. Levels
as high as those found in relapse were seen in others in
remission. LG CIC were frequently found in HSS. The coexis-
tence of LA and LG CIC did not correlate with renal disease
activity and LA and LG CIC were found together during relapse
in one patient without renal involvement.
The incidence of LA CIC was equally high in patients with
IgA nephropathy but levels again proved to be a poor marker of
activity. LA CIC were found in only one of the two patients
followed through a relapse of hematuria. A relationship was not
apparent between the assay results and the state of the disease.
The frequency and levels of LA CIC were as high in patients in
remission as in those patients in relapse.
LA CIC were also found, not only in patients with other
mesangial proliferative lesions, but also in a small sample of
membranous and minimal change sera. Levels of LA CIC alone
or in association with other CIC did not allow a clear distinction
to be drawn between any of the disease groups examined.
Renal immunofluorescence. LG CIC results were compared
with renal IgG deposition in patients with membranous and
mesangial proliferative GN. IgG deposition was subjectively
graded, without knowledge of the CIC results, by scoring the
immunofluorescence of renal biopsy material as negative to 4+.
No correlation was found between LG CIC levels and this score
in either group of patients.
Similarly, LA CIC levels were compared with renal IgA
deposition in all those patients with mesangial proliferative
lesions, including nine HSS patients in whom LA CIC had been
measured, but no relationship was found between LA CIC and
renal IgA deposition.
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Fig. 2. CIC size in two patients with minimal change disease in relapse.
The elution profile of serum proteins from a Sepharose 6B column is
shown as a continuous line with the void volume (> 4 x 106 daltons) to
the left and albumin peak to the right. The positions at which monomer-
ic 1gM and IgG leave the column are indicated. Each fraction collected
was assayed in the LG assay, and inhibition in excess of 5% was plotted
as a vertical bar.
the result of the varying capacities of these assays to detect the
type of complexes present because all current methods detect
only a limited range of complexes. The spectrum of CIC present
in idiopathic GN sera is indicated by the high proportion of sera
which were positive in at least one of the battery of assays we
used, but only a minority of the sera tested were positive by any
single technique. The lack of correlations between our assay
results indicates that each is detecting a substantially different
portion of the CIC pool. The low levels of CIC found may have
contributed to this lack of correlation and accounts for the low
incidence of CIC detected by the Sc assay which proved
relatively insensitive.
Only in minimal change disease did a specific pattern of CIC
emerge. Our finding of non-Clq binding, IgG complexes extends
to an adult population, an observation first made in children by
Levinsky et al [14]. Unlike these authors and others from the
same group [18], however, we have not been able to demon-
strate a link between the levels of CIC found and the activity of
the renal lesion.
Experiments with the autologous immune complex model of
membranous GN have demonstrated the potential importance
01 Jo
MGN
Fig. 1. CIC levels in idiopathic membranous GN. CIC were measured in
the LG assay, (open circle), 80 sera from 36 patients; the Lc assay,
(open triangle), 55 sera from 36 patients; and the Sc assay, (open box),
61 sera from 31 patients. The upper limits of normality in the latex
assays are 20%, and in the Sc assay, 0.4 g/ml, shown as dotted lines.
CIC size. Sera from two patients from each of the minimal
change, membranous, and 1gM mesangial proliferative groups,
all of whom had clinically and biochemically active disease and
high levels of LG dC, were column-fractionated and LG CIC-
estimated. In neither minimal change, (Fig. 2), nor membranous
GN, (Fig. 3), did a specific CIC size predominate. In one patient
with mesangial proliferative GN, who had particularly high
(80% inhibition) serum LG CIC levels and whose disease
followed an unusually rapid course, complexes slightly smaller
than 1gM (9 x i05 daltons) predominated. The second patient
with mesangial proliferative GN had no such peak of a specific
complex size (Fig. 4).
Discussion
CIC levels correlate with disease activity in such systemic
immune complex diseases as systemic lupus erythematosus [7—
9] and in acute poststreptococcal GN [10, 11]. Certain sizes of
CIC appear to have particular pathogenic significance in both
SLE and acute poststreptococcal GN [7, 8, 11]. It has been
suggested that immunochemical characteristics of CIC are
important in determining the manifestations of disease in, for
example, HSS [12] and Wegener's granulomatosis [13]. Our
study was undertaken to determine whether or not similar
considerations apply to an adult population with idiopathic ON.
Results of the application of CIC assays in idiopathic ON
have been variable. A major source of this variation appears to
be the assay used. Certain assays, for example, latex agglutina-
tion inhibition, [141 platelet aggregation [15—17] and lymphocyte
EAC-rosette inhibition [18—20] have been more frequently
positive than others such as the Raji cell radioimmunoassay [17,
21—241 and 1251 Clq-binding assays [17, 21, 24—27]. This may be
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Fig. 3. CIC size in two patients with membranous GN. Both had the
nephrotic syndrome; the top patient had declining renal function.
of in situ immune complex formation in its pathogenesis. This
evidence has been taken, together with reports of a lack of CIC
in human membranous GN [2 1—23, 26, 28—30], to suggest a
similar mechanism of mediation of the human disease [31].
However, CIC may be found in patients with membranous GN
[17, 19, 24, 32, 33], and we have found them in the majority of
our patients by using multiple assays. Neither pattern nor levels
of CIC proved to be a useful guide to disease activity either in
individual patients or in the group as a whole. The finding of
CIC in membranous nephropathy, in the absence of evidence of
a direct role in the renal lesion, leaves open the question of its
pathogenesis.
HSS may be mediated by IgA complexes [12]. CIC have also
been found in other IgA nephropathies [34]. We found such
complexes in a high proportion of sera from patients with both
HSS and IgA nephropathy. They were also present, however,
in a proportion of sera from each of the other histological types
of ON examined. LA CIC levels proved to be less than perfect
markers of disease activity in HSS, and no relation could be
found between LA CIC and activity in Berger's disease. It has
been suggested that the coexistence of IgG and IgA CIC results
in renal injury in HSS [12]. We have not found this pattern to be
exclusive to HSS nephritis, and we have seen it in a patient with
HSS without nephritis and in other forms of ON, with and
without IgA deposition. Patterns of CIC have not proved useful
in distinguishing the subgroups of mesangial proliferative GN
• . . . . . I • • -,
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Fig. 4. CIC size in two patients with 1gM mesangial proliferative GN.
Both had proteinuria and declining renal function.
and, as in membranous GN, although a variety of CIC could be
found in the majority of the patients, levels did not prove to be
useful indicators of activity.
Our failure to demonstrate a relationship between the type of
CIC found and the immunoglobulin deposited in the kidney is in
agreement with other reports [19, 35]. What is present in the
kidney at the time of the biopsy may differ from the material
originally deposited, however, and, in our study, not all CIC
assays were performed on sera taken at the time of the biopsy.
Animal experimental evidence suggests that only certain
sizes of CIC are nephropathic [2]. Further evidence that the
majority of the CIC we have found in GN patients are not linked
directly to the renal lesion is the failure to demonstrate a
predominant size of CIC in five of the six sera we examined.
Levinsky et al have found a similarly wide spectrum of CIC size
in steroid responsive nephrotic syndrome [14] and HSS nephri-
tis [12].
Low levels of a variety of CIC may be found in idiopathic
GN. The pattern of distribution of different types of CIC does
not allow different forms of UN to be distinguished, with the
possible exception of minimal change disease, nor do overall
levels of CIC provide useful information on the clinical state of
the disease. The pool of dC present in these disorders appears
to have little to do with the processes of renal injury. If these
lesions are indeed CIC-mediated, then pathogenetic CIC may
be present in amounts too small or be too rapidly removed from
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the circulation to alter the size or characteristics of a pool of
dC innocent of a direct role in renal injury. That the detected
dC in idiopathic GN have resulted from generalized defects in
antigen handling is suggested by the observation of a prolonged
and enhanced rise in CIC levels following food intake, com-
pared to normal, in these patients [36].
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